Benefit and Harms of New Anti-Cancer Drugs
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11912-013-0303-y.pdf
Reference34 articles.
1. Sargent D. What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions? Oncologist. 2010;15 Suppl 1:19–23. Epub 2010/03/30.
2. • Ocana A, Tannock IF. When are "positive" clinical trials in oncology truly positive? J Natl Cancer Inst. 2011;103(1):16–20. Epub 2010/12/07. This commentary questions what defines a positive clinical trial in oncology and assessed whether recent publications meet the suggested criteria.
3. •• Niraula S, Seruga B, Ocana A, Shao T, Goldstein R, Tannock IF, et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol. 2012;30(24):3012–9. Epub 2012/07/18. This meta-analysis showed that newly approved cancer drugs have significantly higher toxicity than control treatments in randomized trials.
4. Sobrero A, Bruzzi P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol. 2009;27(35):5868–73. Epub 2009/10/15.
5. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23(34):8664–70. Epub 2005/11/02.
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Synthesis and Study of the Structure–Activity Relationship of Antiproliferative N-Substituted Isosteviol-Based 1,3-Aminoalcohols;Pharmaceuticals;2024-02-19
2. Tubulin inhibitors. Selected scaffolds and main trends in the design of novel anticancer and antiparasitic agents;Bioorganic Chemistry;2024-02
3. Classification of CDK2 Inhibitor as Anti-Cancer Agent by Using Simulated Annealing-Support Vector Machine Methods;2022 International Conference on Data Science and Its Applications (ICoDSA);2022-07-06
4. Indazole-based microtubule-targeting agents as potential candidates for anticancer drugs discovery;Bioorganic Chemistry;2022-05
5. Target identification of a novel unsymmetrical 1,3,4‐oxadiazole derivative with antiproliferative properties;Journal of Cellular Physiology;2020-10-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3